View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 4, 2020updated 12 Jul 2022 11:57am

Arrowhead doses first patient in Phase I/II trial of ARO-HSD

US-based biopharmaceutical firm Arrowhead Pharmaceuticals has started dosing subjects in a Phase I/II clinical trial (AROHSD1001) of ARO-HSD for the treatment of patients suffering from alcohol and non-alcohol related liver diseases, such as nonalcoholic steatohepatitis (NASH).

US-based biopharmaceutical firm Arrowhead Pharmaceuticals has started dosing subjects in a Phase I/II clinical trial (AROHSD1001) of ARO-HSD for the treatment of patients suffering from alcohol and non-alcohol related liver diseases, such as nonalcoholic steatohepatitis (NASH).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NASH is a type of non-alcoholic fatty liver disease (NAFLD). It occurs due to inflammation and damage caused by a build-up of fat in the liver.

The single and multiple dose-escalating trial AROHSD1001 will evaluate the safety and efficacy of the company’s first investigational RNA interference (RNAi) medicine ARO-HSD in about 74 healthy volunteers identified with NASH or suspected NASH.

It will also evaluate the pharmacokinetics and pharmacodynamic effects of ARO-HSD.

Other exploratory objectives of the study include the analysis of several measures of drug activity using liver biopsy.

Arrowhead Pharmaceuticals chief medical officer Javier San Martin said: “Genetic studies have recently pointed to HSD17B13 as a compelling target for multiple forms of liver disease.

“No other therapeutics against this target have reached clinical studies, so ARO-HSD is the first investigational medicine using any modality to initiate a clinical program to study whether HSD17B13 inhibition in the liver leads to a clinical benefit for patients.

“Further, based on our preclinical work and key findings from various studies with our other product candidates, we believe that an RNAi-based intervention that utilizes our proprietary TRiM platform has the potential to be highly active at silencing the expression of HSD17B13.”

HSD17B13 falls under the hydroxysteroid dehydrogenase (HSD) family, which is involved in the fatty acids and bile acids metabolism.

In August last year, Arrowhead Pharmaceuticals initiated a potentially pivotal Phase II/III clinical trial of ARO-AAT, its second-generation subcutaneously administered RNAi therapeutic.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena